Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 794.1 USD -11.66% Market Closed
Market Cap: 752.8B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 1 036.37 USD with a low forecast of 808 USD and a high forecast of 1 249.5 USD.

LLY Lowest Forecast
Wall Street Target
808 USD
2% Upside
LLY Average Forecast
Wall Street Target
1 036.37 USD
31% Upside
LLY Highest Forecast
Wall Street Target
1 249.5 USD
57% Upside
Lowest
Price Target
808 USD
2% Upside
Average
Price Target
1 036.37 USD
31% Upside
Highest
Price Target
1 249.5 USD
57% Upside
Eli Lilly and Co Competitors:
Price Targets
BMY
Bristol-Myers Squibb Co
17% Upside
ROG
Roche Holding AG
17% Upside
SANOFI
Sanofi India Ltd
36% Upside
N
4516
Nippon Shinyaku Co Ltd
18% Upside
BMY
Bristol-Myers Squibb Co
17% Upside
ROG
Roche Holding AG
17% Upside
SANOFI
Sanofi India Ltd
36% Upside
N
4516
Nippon Shinyaku Co Ltd
18% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
21% Upside
CRON
Cronos Group Inc
43% Upside
VY4
SNDL Inc
162% Upside

Revenue
Forecast

Revenue Estimate
Eli Lilly and Co

For the last 8 years the compound annual growth rate for Eli Lilly and Co's revenue is 10%. The projected CAGR for the next 3 years is 23%.

10%
Past Growth
23%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Eli Lilly and Co

For the last 8 years the compound annual growth rate for Eli Lilly and Co's operating income is 20%. The projected CAGR for the next 3 years is 33%.

20%
Past Growth
33%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Eli Lilly and Co

For the last 8 years the compound annual growth rate for Eli Lilly and Co's net income is 18%. The projected CAGR for the next 3 years is 49%.

18%
Past Growth
49%
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LLY's stock price target?
Price Target
1 036.37 USD

According to Wall Street analysts, the average 1-year price target for LLY is 1 036.37 USD with a low forecast of 808 USD and a high forecast of 1 249.5 USD.

What is Eli Lilly and Co's Revenue forecast?
Projected CAGR
23%

For the last 8 years the compound annual growth rate for Eli Lilly and Co's revenue is 10%. The projected CAGR for the next 3 years is 23%.

What is Eli Lilly and Co's Operating Income forecast?
Projected CAGR
33%

For the last 8 years the compound annual growth rate for Eli Lilly and Co's operating income is 20%. The projected CAGR for the next 3 years is 33%.

What is Eli Lilly and Co's Net Income forecast?
Projected CAGR
49%

For the last 8 years the compound annual growth rate for Eli Lilly and Co's net income is 18%. The projected CAGR for the next 3 years is 49%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 251,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.